Related Experiment Videos
Mortality in sickle cell patients on hydroxyurea therapy.
Sule M Bakanay1, Erin Dainer, Betsy Clair
1Sickle Cell Center, Department of Medicine, Office of Biostatistics and Bioinformatics, Medical College of Georgia, Augusta 30912, USA.
Blood
|September 30, 2004
Summary
Hydroxyurea (HU) is effective for sickle cell disease, but some patients still die. Older patients, those with anemia, and higher organ damage markers on HU require earlier intervention for better outcomes.
Area of Science:
- Hematology
- Clinical Medicine
- Genetics
Background:
- Hydroxyurea (HU) is a standard treatment for sickle cell disease (SCD), reducing mortality.
- Despite HU therapy, a significant number of SCD patients succumb to disease complications.
Purpose of the Study:
- To identify factors associated with mortality in sickle cell patients undergoing hydroxyurea treatment.
- To characterize a subgroup of patients at higher risk of death despite HU therapy.
Main Methods:
- Retrospective analysis of 226 sickle cell patients treated with HU.
- Comparison of clinical characteristics, laboratory values, and genetic haplotypes between deceased and surviving patients.
- Identification of causes of death, with a focus on acute chest syndrome (ACS).
Main Results:
- 38 out of 226 patients died, predominantly from SCD-related causes (34 patients).
- Acute chest syndrome (ACS) was the leading cause of death (35%).
- Deceased patients were older at HU initiation, had higher anemia, elevated BUN and creatinine, and specific genetic haplotypes (BAN or CAM).
- No significant differences were observed in HU dose or fetal hemoglobin (Hb F) response between groups.
Conclusions:
- Sickle cell patients dying on HU therapy may belong to a distinct subgroup characterized by older age at treatment initiation, more severe disease, and greater organ damage.
- Early identification and prompt initiation of hydroxyurea are crucial for this high-risk subgroup.
- Further research into identifying and managing risk factors for mortality in SCD patients on HU is warranted.